Intellia Therapeutics to Present at Morgan Stanley Healthcare Conference
Event summary
- Intellia Therapeutics will present at Morgan Stanley's 24th Annual Global Healthcare Conference on September 14, 2026, at 4:05 p.m. ET.
- The presentation will be available via live webcast on Intellia's website and replayed for 90 days.
- Intellia is a clinical-stage biopharmaceutical company focused on CRISPR gene editing technologies.
The big picture
Intellia's participation in the Morgan Stanley conference underscores its push to solidify its position in the CRISPR gene editing market. The event provides a platform to showcase its pipeline and attract potential partners or investors, amid a landscape where gene editing technologies are rapidly evolving and facing intense competition. The strategic focus will be on demonstrating differentiated therapeutic approaches and clinical success rates.
What we're watching
- Pipeline Progress
- How Intellia's presentation will highlight advancements in its CRISPR-based therapies and their clinical trial progress.
- Investor Sentiment
- Whether the presentation will bolster investor confidence amid competitive pressures in the gene editing space.
- Strategic Partnerships
- The pace at which Intellia can secure new collaborations or licensing deals following the conference.